105 related articles for article (PubMed ID: 26447381)
1. Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer.
Quián YP; Crombet T; Batista JF; Prats A; Perera A
Clin Nucl Med; 2016 Mar; 41(3):244-6. PubMed ID: 26447381
[TBL] [Abstract][Full Text] [Related]
2. Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351).
Chengazi VU; Feneley MR; Ellison D; Stalteri M; Granowski A; Granowska M; Nimmon CC; Mather SJ; Kirby RS; Britton KE
J Nucl Med; 1997 May; 38(5):675-82. PubMed ID: 9170426
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer imaging with a new monoclonal antibody: a preliminary report.
Sanford E; Grzonka R; Heal A; Helal M; Persky L; Tyson I
Ann Surg Oncol; 1994 Sep; 1(5):400-4. PubMed ID: 7850541
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
5. The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
Binnie D; Divoli A; McCready VR; Dearnaley D; Flux G
Cancer Biother Radiopharm; 2005 Apr; 20(2):189-94. PubMed ID: 15869454
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer.
Lacić M; Bokulić T; Lukac J; Kovacić K; Baum RP; Kusić Z
Nucl Med Commun; 1999 Feb; 20(2):135-43. PubMed ID: 10088162
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
Begic A; Kucukalic-Selimovic E; Obralic N; Duric O; Lacevic N; Begovic-Hadzimuratovic S; Skopljak A; Dzubur-Aganovic M
Med Arh; 2006; 60(1):54-5. PubMed ID: 16425536
[TBL] [Abstract][Full Text] [Related]
8. Radioimaging of the prostate and metastases of prostatic carcinoma with 99mTc-labelled prostatic acid phosphatase-specific antibodies and their Fab fragments.
Vihko P; Heikkilä J; Kontturi M; Wahlberg L; Vihko R
Ann Clin Res; 1984; 16(1):51-2. PubMed ID: 6742767
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases.
Garcia JR; Simo M; Perez G; Soler M; Lopez S; Setoain X; Lomeña F
Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1714. PubMed ID: 14625662
[No Abstract] [Full Text] [Related]
10. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
11. Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase.
Goldenberg DM; DeLand FH
Urol Clin North Am; 1984 May; 11(2):277-81. PubMed ID: 6328719
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
[TBL] [Abstract][Full Text] [Related]
13. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
14. The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
Takahashi N; Inoue T; Lee J; Yamaguchi T; Shizukuishi K
Oncology; 2007; 72(3-4):226-33. PubMed ID: 18176088
[TBL] [Abstract][Full Text] [Related]
15. [Radiologic follow-up and prognosis of efficiency of systemic Sr-89 Cl-2 therapy of bone metastases in prostate cancer].
Barysheva EV; Obradovic V; Stefanovic L; Riannel' IuE; Regoe S; Selivanov SP; Artiko V; Isaeva SN; Velichko SA; Tuzikov SA; Ussov VIu
Vestn Rentgenol Radiol; 2000; (6):46-50. PubMed ID: 12717912
[TBL] [Abstract][Full Text] [Related]
16. Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion.
Bombardieri E; Setti L; Kirienko M; Antunovic L; Guglielmo P; Ciocia G
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):381-99. PubMed ID: 26337240
[TBL] [Abstract][Full Text] [Related]
17. Quantitative bone scan and bone metastases in prostatic cancer.
Grob JC; Thiel J; Méthlin G; Wolf P; Bollack C
Urol Int; 1985; 40(1):45-7. PubMed ID: 3156441
[TBL] [Abstract][Full Text] [Related]
18. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma.
Oyen WJ; Witjes JA; Corstens FH
Eur Urol; 2001 Sep; 40(3):294-9. PubMed ID: 11684845
[TBL] [Abstract][Full Text] [Related]
19. [Skeletal scintigraphy for the observation of course and treatment of carcinoma of the prostate ].
Pabst HW; Langhammer H; Schmid L; Sintermann R
Rofo; 1981 Jul; 135(1):44-9. PubMed ID: 6288532
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
